{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-168545","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.439662+00:00","generated_at":"2026-06-01T01:36:59.236867+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intellia Therapeutics appoints Edward Dulac as CFO; Glenn Goddard steps down June 30, 2024","bullets":["Edward Dulac appointed EVP, CFO, and Treasurer, effective July 22, 2024.","Glenn Goddard steps down as CFO effective June 30, 2024; departure not related to any disagreement.","Michael P. Dube (CAO) to serve as interim principal financial officer until Dulac's start date.","Dulac receives $510K base salary, 40% target bonus, $100K sign-on bonus, and equity awards of ~$4.2M.","Board approved 2024 Inducement Plan reserving 850,000 shares for new employee equity grants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-168545","json":"https://secwatch.observer/filing/0001193125-24-168545.json","markdown":"https://secwatch.observer/filing/0001193125-24-168545.md","text":"https://secwatch.observer/filing/0001193125-24-168545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/d822257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:36:59.236867+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04c35e14f9","claim":"Michael P. Dube was appointed as interim principal financial officer at Intellia Therapeutics, Inc..","evidence_excerpt":"Michael P. Dube, the Company’s Chief Accounting Officer, will serve as the Company’s interim principal financial officer until the Start Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"27ab38b769","claim":"Edward Dulac was appointed as Executive Vice President and Chief Financial Officer at Intellia Therapeutics, Inc..","evidence_excerpt":"the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ed94baa362","claim":"Glenn Goddard departed as Chief Financial Officer at Intellia Therapeutics, Inc..","evidence_excerpt":"the Company also announced that Glenn Goddard, the Company’s current CFO, will step down effective June 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312524168545/0001193125-24-168545-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}